HMPL-A580 / Hutchmed - LARVOL DELTA

HUTCHMED (China) Limited…announces that it has initiated a Phase I/IIa clinical trial of HMPL-A580, HUTCHMED’s second novel Antibody-Targeted Therapy Conjugate (“ATTC”), in patients with unresectable, advanced or metastatic solid tumors in China and the US. (GlobeNewswire) - "The first patient received the first dose on March 4, 2026."

Trial status • Oncology • Solid Tumor